Fluorodesoxiglucosa

EN Texto en inglés Aún no hay artículo en tu idioma: extracto en inglés.

[18F]Fluorodeoxyglucose (INN), or fluorodeoxyglucose F 18 (USAN and USP), also commonly called fluorodeoxyglucose and abbreviated [18F]FDG, 2-[18F]FDG or FDG, is a radiopharmaceutical, specifically a radiotracer, used in the medical imaging modality positron emission tomography (PET). Chemically, it is 2-deoxy-2-[18F]fluoro-D-glucose, a glucose analog, with the positron-emitting radionuclide fluorine-18 substituted for the normal hydroxyl group at the C-2 position in the glucose molecule. The uptake of [18F]FDG by tissues is a marker for the tissue uptake of glucose, which in turn is closely correlated with certain types of tissue metabolism. After [18F]FDG is injected into a patient, a PET scanner can form two-dimensional or three-dimensional images of the distribution of [18F]FDG within the body. Since its development in 1976, [18F]FDG has had a profound influence on research in the neurosciences. The subsequent discovery in 1980 that [18F]FDG accumulates in tumors underpins the evolution of PET as a major clinical tool in cancer diagnosis. [18F]FDG is now the standard radiotracer used for PET neuroimaging and cancer patient management. The images can be assessed by a nuclear medicine physician or radiologist to provide diagnoses of various medical conditions.